Related Experiment Video
Updated: May 30, 2026
16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
The total artificial heart.
1Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY, USA. mark.slaughter@louisville.edu
Panminerva Medica
|July 22, 2011
Summary
Total artificial hearts (TAH) have limited use, but the Syncardia/CardioWest TAH remains viable for biventricular failure. Continuous flow ventricular assist devices (VAD) show growing acceptance and improved outcomes.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Medical Devices
Background:
- Total artificial hearts (TAH) were developed in the 1960s for severe heart failure.
- TAH use has been limited, failing to meet early expectations as a heart transplant alternative.
- Continuous flow ventricular assist devices (VAD) have advanced significantly, gaining widespread clinical acceptance.
Purpose of the Study:
- To review the evolution of TAH devices.
- To discuss the current clinical use of TAH.
- To present the emerging use of continuous flow VAD technology for biventricular support.
Main Methods:
- Historical review of TAH development.
- Analysis of current clinical data for TAH and VAD.
- Discussion of technological advancements in VAD and TAH systems.
Main Results:
- The Syncardia/CardioWest TAH has supported over 900 patients, with a 79% survival rate as a bridge-to-transplantation.
- TAH implantations remain low compared to the increasing number of LVAD implants.
- New portable drivers are enabling TAH patient discharge.
Conclusions:
- The Syncardia/CardioWest TAH is a viable option for severe biventricular failure and end-organ dysfunction.
- Continuous flow VAD technology is rapidly evolving and gaining clinical acceptance.
- Future directions include integrated VAD and TAH systems for chronic biventricular support.
